Credit: Shutterstock. This clinical report from the American Academy of Pediatrics is an update on their 2007 clinical report. HealthDay News — All caregivers for children at risk of anaphylaxis ...
Findings from a study published in the Annals of Allergy, Asthma & Immunology suggest the ongoing difficulty in diagnosing anaphylaxis as evident by the low prescribing rates of epinephrine ...
Please provide your email address to receive an email when new articles are posted on . ATLANTA — Researchers are developing an app to educate teenagers on epinephrine auto-injector use in anaphylaxis ...
Pro Football Player Adrian Peterson is Calling on Americans to be Ready2Go™ and Learn How to be Aware and Prepared for Anaphylaxis PITTSBURGH, June 2, 2014 /PRNewswire/ -- Mylan Specialty, the fully ...
Dublin, April 30, 2020 (GLOBE NEWSWIRE) -- The "Epinephrine Auto-Injector Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering. The Global ...
Richmond, Virginia, May 15, 2025 (GLOBE NEWSWIRE) -- New findings from a retrospective analysis of U.S. commercial claims data indicate that patients prescribed AUVI-Q® (epinephrine injection, USP) ...
Epinephrine auto-injectors are the mainstay of emergency treatment for anaphylactic allergic reactions, but despite many years of widespread use, important questions about them remain unanswered. At ...
AUVI-Q (R) (epinephrine injection, USP) is still available by prescription for children with life-threatening allergies. Most kids spend the final weeks of summer amassing school supplies and cramming ...
The U.S. Food and Drug Administration today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those ...
Anaphylaxis can cause severe itching, difficulty breathing, fainting, and abdominal pain. These symptoms usually begin about 30 minutes after coming into contact with an allergy trigger. First, call ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results